Prolistem® at the ASRM– Denver Colorado

We are honored to participate in the prestigious ASRM 2024 Conference in Denver, Colorado, a cornerstone event in the world of reproductive medicine. This gathering unites leading experts, innovators, and pioneers in the field, providing an unparalleled platform for unveiling cutting-edge technologies, groundbreaking treatments, and transformative research that redefine the future of fertility care.

At this year’s conference, we proudly presented the findings of a third-party clinical study highlighting the efficacy of Prolistem, our novel supplement, in addressing one of the most challenging aspects of male infertility: non-obstructive azoospermia (NOA).

Clinical Study Overview

Objective

The study evaluated Prolistem’s effectiveness in enhancing the success rates of microdissection testicular sperm extraction (MicroTESE) for men diagnosed with NOA.

Materials and Methods

A randomized study was conducted involving 40 NOA patients, divided into two groups:

• Prolistem Group: Patients (n=20) received Prolistem® for six months prior to MicroTESE.
• Control Group: Patients (n=20) were given standard multivitamins.

The primary endpoint was the success rate of sperm extraction during MicroTESE.

Results

• Prolistem Group: 12 out of 20 patients (60%) achieved successful sperm extraction.
• Control Group: Only 4 out of 20 patients (20%) had successful outcomes.

Conclusion

The study demonstrated that Prolistem supplementation significantly improves the likelihood of sperm extraction during MicroTESE compared to standard multivitamin supplementation. These results underscore Prolistem’s potential as a therapeutic intervention for men with NOA, offering hope to individuals and couples facing male infertility challenges.

Impact Statement

Prolistem represents a promising breakthrough in male infertility management, potentially revolutionizing treatment options for NOA patients. Continued research and clinical validation are critical to unlocking its full potential and broadening its impact in reproductive medicine.

Link to the study: https://www.fertstert.org/article/S0015-0282(24)01442-0/fulltext#:~:text=successful%20sperm%20extraction.-,CONCLUSIONS,fertility%20outcomes%20in%20NOA%20patients.

Our participation in ASRM 2024 reflects our commitment to driving innovation, collaborating with thought leaders, and delivering science-backed solutions that transform lives. This conference serves as a powerful catalyst for growth, equipping us with cutting-edge insights to enhance the care we provide to patients worldwide. We look forward to advancing the conversation on fertility and making meaningful contributions to this dynamic and evolving field.